Tsuyoshi Fukuda, PhD

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-803-0428

Fax 513-636-0168

Email tsuyoshi.fukuda@cchmc.org

Clinical pharmacology (pharmacogenetics, pharmacokinetics and pharmacodynamics)

Dr. Fukuda received his pharmacy degree and PhD in pharmaceutical science from Osaka University, Japan. He received postdoctoral training in the Division of Clinical Pharmacology and Pharmacogenomics (Prof. J. Azuma, MD) and served as an assistant professor at Osaka University, Graduate School of Pharmaceutical Sciences. He joined the Division of Clinical Pharmacology (Prof. Alexander A. Vinks, PharmD, PhD) at Cincinnati Children's Hospital Medical Center in 2007. He spent around 20 years in the field of clinical pharmacology while engaged in pharmacogenetic (PG) and pharmacokinetic-pharmacodynamic (PK/PD) research. His current research interests include the clinical application of integrated PK/PD/PG modeling and simulation and physiologically based pharmacokinetic (PBPK) analysis with developmental pharmacology, focusing on improving our understanding of inter-patient differences in drug response and developing individualized dosing strategies in pediatric patients.

Dr. Fukuda’s efforts have resulted in over 70 peer-reviewed publications with project members that include master's and PhD students, research fellows, clinical fellows, pharmacists, physicians, and private sector R & D staff.

BS: Osaka University, School of Pharmacy, Osaka, Japan, 1995.

Pharmacist: Japan, 1995.

MS: Osaka University, Osaka, Japan, 1997.

PhD: Osaka University, Osaka, Japan, 2000.

Certification: Clinical Pharmacology (Pharmacist), 2003 (Japanese Society of Clinical Pharmacology), 2008 renewed.

View PubMed Publications

Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, Dixon BP, Chima RS, Hirsch R, Teusink A, Lazear D, Lane A, Myers KC, Dandoy CE, Davies SM. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Feb;22(2):307-15.

Emoto C, Fukuda T, Johnson TN, Adams DM, Vinks AA. Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants. CPT Pharmacometrics Syst Pharmacol. 2015 Feb;4(2):e17.

Emoto C, Fukuda T, Venkatasubramanian R, Vinks AA. The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model. Br J Clin Pharmacol. 2015 Dec;80(6):1438-46.

Vinks AA, Emoto C, Fukuda T. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children. Clin Pharmacol Ther. 2015 Sep;98(3):298-308.

Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014 Apr;20(4):518-25.

Mizuno T, Fukuda T, Masuda S, Uemoto S, Matsubara K, Inui KI, Vinks AA. Developmental trajectory of intestinal MDR1/ABCB1 expression in children. Br J Clin Pharmacol. 2014 May;77(5):910-2.

Dong M, Fukuda T, Vinks AA. Optimization of mycophenolic acid therapy using clinical pharmacometrics. Drug Metab Pharmacokinet. 2014;29(1):4-11.

Emoto C, Fukuda T, Cox S, Christians U, Vinks AA. Development of a physiologically-based pharmacokinetic model for sirolimus: predicting bioavailability based on intestinal CYP3A content. CPT Pharmacometrics Syst Pharmacol. 2013 Jul 24;2:e59.

Fukuda T, Chidambaran V, Mizuno T, Venkatasubramanian R, Ngamprasertwong P, Olbrecht V, Esslinger HR., Vinks AA, Sadhasivam S. Organic Cation Transporter 1 Genetic Variants influence the pharmacokinetics of Morphine in Children. Pharmacogenomics. 2013 Jul;14(10):1141-51.

Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D. Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med. 2013 Jul;39(7):1247-52.